The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to grow and a cancer biotech cut staff.
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to grow and a cancer biotech cut staff.
